FAPI-04 PET/CT Using [F]AlF Labeling Strategy: Automatic Synthesis, Quality Control, and Assessment in Patient

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Apr 5

PMID 33816303

Citations 27

Authors

Xiao Jiang

Xiaoxiong Wang

Taipeng Shen

Yutang Yao

Meihua Chen

Zeng Li

Xiuli Li

Jiaqi Shen

Ying Kou

Shirong Chen

Xing Zhou

Zhifu Luo

Zhuzhong Cheng

Affiliations

Soon will be listed here.

Abstract

Ga labeled FAPI is the current standard for FAPI-PET, but its batch activity is limited. [F]AlF-NOTA-FAPI-04 is a promising alternative combining the advantages of a chelator-based radiolabeling method with the unique properties of fluorine-18. The objective of this study was to develop a quick automatic method for synthesis of [F]AlF-NOTA-FAPI-04 using a AllinOne synthesis system, and perform PET imaging with [F]AlF-NOTA-FAPI-04 on patients. [F]AlF-NOTA-FAPI-04 was produced, and its quality control was conducted by HPLC equipped with a radioactive detector. [F]AlF-NOTA-FAPI-04 PET/CT imaging was performed in normal BALB/c mice (n = 3) and 4T1 breast cancer models (n = 3) to determine its biodistribution. Then [F]AlF-NOTA-FAPI-04 and F-fluorodeoxyglucose (FDG) PET/CT imaging were performed in an invasive ductal carcinoma patient (female, 54 years old). The synthesis time of [F]AlF-NOTA-FAPI-04 was about 25 min, and the radiochemical yield was 26.4 ± 1.5% (attenuation correction, n = 10). The radiochemical purity was above 99.0% and was above 98.0% after 6 h. The product was colorless transparent solution with pH value of 7.0-7.5, and the specific activity was 49.41 ± 3.19 GBq/μmol. PET/CT imaging in mice showed that physiological uptake of [F]AlF-NOTA-FAPI-04 was mainly in the biliary system and bladder, and [F]AlF-NOTA-FAPI-04 highly concentrated in tumor xenografts. PET/CT imaging in the patient showed that [F]AlF-NOTA-FAPI-04 obtained high tumor background ratio (TBR) value of 8.44 in segment V and VI, while TBR value was 2.55 by F-FDG. [F]AlF-NOTA-FAPI-04 could be synthesized with high radiochemical yield and batch production by AllinOne module and show excellent diagnosis performance in cancer patients.

Citing Articles

Comparison of Al[F]-NOTA-FAPI-04 PET/CT and [F]-FDG PET/CT in a patient with lung cancer and pulmonary tuberculosis: a case report and literature review.

Qin J, Yu J, Wei Y Front Oncol. 2025; 15:1470132.

PMID: 39963103 PMC: 11830580. DOI: 10.3389/fonc.2025.1470132.

Non-invasive assessment of IgA nephropathy severity with [F]AlF-NOTA-FAPI-04 PET/CT imaging.

Wang H, He L, Feng L, Zhang W, Liu N, Zhang W Clin Kidney J. 2024; 17(12):sfae340.

PMID: 39664991 PMC: 11632375. DOI: 10.1093/ckj/sfae340.

Evaluating the diagnostic performance of [F]ALF-NOTA-FAPI-04 PET/CT in gastric cancer: a comparative study with [F]FDG PET/CT.

Lv J, Zheng K, Jiang C, Yang J, Peng X, Ye H Eur Radiol. 2024; .

PMID: 39604653 DOI: 10.1007/s00330-024-11219-z.

Impact of fat intake on [F]AlF-NOTA-FAPI-04 uptake in normal abdominal organs.

Dai J, Zhou W, Liu H, Jiang C, Ye H Front Med (Lausanne). 2024; 11:1464779.

PMID: 39574915 PMC: 11578823. DOI: 10.3389/fmed.2024.1464779.

Combined PET Radiotracer Approach Reveals Insights into Stromal Cell-Induced Metabolic Changes in Pancreatic Cancer In Vitro and In Vivo.

Doctor A, Laube M, Meister S, Kiss O, Kopka K, Hauser S Cancers (Basel). 2024; 16(19).

PMID: 39410013 PMC: 11475921. DOI: 10.3390/cancers16193393.

References

Payne K, Woods M . Isomerism in benzyl-DOTA derived bifunctional chelators: implications for molecular imaging. Bioconjug Chem. 2015; 26(2):338-44. DOI: 10.1021/bc500593h. View

Schreiber H, Rowley D . Cancer. Awakening immunity. Science. 2010; 330(6005):761-2. DOI: 10.1126/science.1198345. View

Varasteh Z, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N . Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04. J Nucl Med. 2019; 60(12):1743-1749. PMC: 6894377. DOI: 10.2967/jnumed.119.226993. View

Giesel F, Kratochwil C, Lindner T, Marschalek M, Loktev A, Lehnert W . Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2018; 60(3):386-392. PMC: 6424229. DOI: 10.2967/jnumed.118.215913. View

Tircso G, Webber B, Kucera B, Young V, Woods M . Analysis of the conformational behavior and stability of the SAP and TSAP isomers of lanthanide(III) NB-DOTA-type chelates. Inorg Chem. 2011; 50(17):7966-79. PMC: 3204396. DOI: 10.1021/ic2012843. View

Laverman P, DSouza C, Eek A, McBride W, Sharkey R, Oyen W . Optimized labeling of NOTA-conjugated octreotide with F-18. Tumour Biol. 2011; 33(2):427-34. PMC: 3296034. DOI: 10.1007/s13277-011-0250-x. View

Mueller M, Fusenig N . Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004; 4(11):839-49. DOI: 10.1038/nrc1477. View

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J . Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med. 2018; 59(9):1415-1422. DOI: 10.2967/jnumed.118.210443. View

Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D . A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018; 59(9):1423-1429. PMC: 6126438. DOI: 10.2967/jnumed.118.210435. View

10.

Tran E, Chinnasamy D, Yu Z, Morgan R, Lee C, Restifo N . Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013; 210(6):1125-35. PMC: 3674706. DOI: 10.1084/jem.20130110. View

11.

Laverman P, McBride W, Sharkey R, Eek A, Joosten L, Oyen W . A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med. 2010; 51(3):454-61. PMC: 2908260. DOI: 10.2967/jnumed.109.066902. View

12.

Pauwels E, Cleeren F, Tshibangu T, Koole M, Serdons K, Dekervel J . [F]AlF-NOTA-octreotide PET imaging: biodistribution, dosimetry and first comparison with [Ga]Ga-DOTATATE in neuroendocrine tumour patients. Eur J Nucl Med Mol Imaging. 2020; 47(13):3033-3046. DOI: 10.1007/s00259-020-04918-4. View

13.

Schlesinger J, Rajander J, Ihalainen J, Ramesh D, Eklund P, Fagerholm V . Isomerism of [64Cu-NOTA-Bn]-labeled radiotracers: separation of two complex isomers and determination of their interconversion energy barrier using ion pair chromatography. Inorg Chem. 2011; 50(10):4260-71. DOI: 10.1021/ic101775q. View

14.

Dolznig H, Schweifer N, Puri C, Kraut N, Rettig W, Kerjaschki D . Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun. 2005; 5:10. View

15.

Kakarla S, Chow K, Mata M, Shaffer D, Song X, Wu M . Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013; 21(8):1611-20. PMC: 3734659. DOI: 10.1038/mt.2013.110. View

16.

Wang H, Wu Q, Liu Z, Luo X, Fan Y, Liu Y . Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis. 2014; 5:e1155. PMC: 5424105. DOI: 10.1038/cddis.2014.122. View

17.

McBride W, DSouza C, Sharkey R, Karacay H, Rossi E, Chang C . Improved 18F labeling of peptides with a fluoride-aluminum-chelate complex. Bioconjug Chem. 2010; 21(7):1331-40. PMC: 2913283. DOI: 10.1021/bc100137x. View

18.

McBride W, Sharkey R, Karacay H, DSouza C, Rossi E, Laverman P . A novel method of 18F radiolabeling for PET. J Nucl Med. 2009; 50(6):991-8. DOI: 10.2967/jnumed.108.060418. View

19.

Brennen W, Rosen D, Wang H, Isaacs J, Denmeade S . Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst. 2012; 104(17):1320-34. PMC: 3529592. DOI: 10.1093/jnci/djs336. View

20.

Giesel F, Adeberg S, Syed M, Lindner T, Jimenez-Franco L, Mavriopoulou E . FAPI-74 PET/CT Using Either F-AlF or Cold-Kit Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J Nucl Med. 2020; 62(2):201-207. PMC: 8679591. DOI: 10.2967/jnumed.120.245084. View